论文部分内容阅读
目的:研制肝癌特异性多柔比星免疫磷脂纳米粒。方法:先制备出多柔比星聚氰基丙烯酸正丁酯毫微粒,再采用磷脂双分子层包裹,得到多柔比星磷脂纳米粒;将抗酸性铁蛋白单克隆抗体(McAb-PAF)与其相联,最后得到肝癌特异性多柔比星免疫磷脂纳米粒。并对其制备工艺、特性、细胞毒性、体内靶向性等进行了探讨。结果:制得的多柔比星免疫磷脂纳米粒粒径为97.2nm,抗体结合率78.8％,抗体活性保持良好;多柔比星免疫磷脂纳米粒对肝癌细胞的杀伤作用明显强于游离的多柔比星和普通脂质体;对于肝癌细胞荷瘤裸鼠,免疫磷脂纳米粒组较普通脂质体组抑瘤率有显著性差异。结论:肝癌特异性多柔比星免疫磷脂纳米粒,有可能成为一种新的药物靶向载体系统。
Objective: To develop hepatoma-specific doxorubicin-immunized phospholipid nanoparticles. Methods: Doxorubicin polybutylcyanoacrylate nanoparticles were prepared and encapsulated with phospholipid bilayer to obtain doxorubicin phospholipid nanoparticles. Anti-acid ferritin monoclonal antibody (McAb-PAF) Associated with the final liver-specific doxorubicin immune phospholipid nanoparticles. And its preparation process, characteristics, cytotoxicity, in vivo targeting were discussed. Results: The dosages of doxorubicin-immunized phospholipid nanoparticles were 97.2nm, the antibody binding rate was 78.8%, and the antibody activity was maintained well. The killing effect of doxorubicin-immunized phospholipid nanoparticles on hepatoma cells was significantly stronger than that of free Rhabositide and common liposomes. For hepatocellular carcinoma cell-bearing nude mice, the immunolipid-containing NPs had significantly different inhibition rates compared with the normal liposomes. Conclusion: The hepatoma-specific doxorubicin-immunized phospholipid nanoparticles may become a new drug targeting vector system.